CHLORHEXIDINE

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category Free-form
ATC A01AB03 B05CA02 D08AC02 D09AA12 R02AA05 S01AX09 S02AA09 S03AA04
UNII R4KO0DY52L
EPA CompTox DTXSID2033314

Structure

InChI Key GHXZTYHSJHQHIJ-UHFFFAOYSA-N
Smiles N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1
InChI
InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)

Physicochemical Descriptors

Property Name Value
Molecular Formula C22H30Cl2N10
Molecular Weight 505.46
AlogP 4.18
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 10.0
Number of Rotational Bond 9.0
Polar Surface Area 167.58
Molecular species BASE
Aromatic Rings 2.0
Heavy Atoms 34.0
Assay Description Organism Bioactivity Reference
Inhibitory activity against HIV-1 integrase at 1 mM Human immunodeficiency virus 1 50.0 %
Inhibitory activity against HIV-1 integrase at 200 uM Human immunodeficiency virus 1 50.0 %
Inhibitory activity against HIV-1 integrase at 25 uM None 50.0 %
Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 0.1 ug/ml relative to BHIS control relative to BHIS control Streptococcus mutans 103.5 %
Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 1200 ug/ml relative to BHIS control Streptococcus mutans 34.5 %
Antimicrobial activity against Streptococcus mutans JM11 assessed as inhibition of bacterial biofilm formation at 50 uM after 10 mins Streptococcus mutans 95.0 %
Antimicrobial activity against Streptococcus oralis assessed as inhibition of bacterial biofilm formation at 50 uM after 10 mins Streptococcus oralis 95.0 %
Antimicrobial activity against Streptococcus gordonii assessed as inhibition of bacterial biofilm formation at 50 uM after 10 mins Streptococcus gordonii 95.0 %
Antimicrobial activity against Streptococcus sanguinis assessed as inhibition of bacterial biofilm formation at 50 uM after 10 mins Streptococcus sanguinis 95.0 %
Antimicrobial activity against Streptococcus mitis assessed as inhibition of bacterial biofilm formation at 50 uM after 10 mins Streptococcus mitis 95.0 %
Antimicrobial activity against Streptococcus salivarius assessed as inhibition of bacterial biofilm formation at 50 uM after 10 mins Streptococcus salivarius 95.0 %
PUBCHEM_BIOASSAY: Fluorescence Cell-Based Retest of Candida albicans Growth in the Presence of Fluconazole. (Class of assay: confirmatory) [Related pubchem assays: 2007 (Project Summary), 1979 (Primary HTS)] None 649.0 nM
PUBCHEM_BIOASSAY: Luminescence Cell-Based/Microorganism Dose Confirmation HTS to Identify Inhibitors of Trypanosoma cruzi Replication. (Class of assay: confirmatory) [Related pubchem assays: 1885, 1968 ] None 178.0 nM
Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Homo sapiens 410.0 nM
Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Homo sapiens 210.0 nM
Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Homo sapiens 400.0 nM
Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Homo sapiens 500.0 nM
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay Homo sapiens 86.0 %
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Homo sapiens 700.0 nM
PubChem BioAssay. SNU-C1 viability from Cell TiterGlo-IC50. (Class of assay: confirmatory) None 438.6 nM
Antimicrobial activity against Streptococcus mutans ATCC 35668 biofilm at 0.2 % after 1 hr by MTT assay relative to control Streptococcus mutans 93.6 %
Antimicrobial activity against Candida albicans ATCC 90028 biofilm at 0.2 % after 1 hr by MTT assay relative to control Candida albicans 49.9 %
Antitrypanosomal activity against Trypanosoma brucei brucei expressing BS449 after 24 hrs by ATPlite-luciferase reporter gene assay Trypanosoma brucei brucei 430.0 nM
Antitrypanosomal activity against Trypanosoma brucei brucei expressing BS449 after 48 hrs by ATPlite-luciferase reporter gene assay Trypanosoma brucei brucei 410.0 nM
Antitrypanosomal activity against Trypanosoma brucei brucei expressing BS449 after 72 hrs by ATPlite-luciferase reporter gene assay Trypanosoma brucei brucei 430.0 nM
Antitrypanosomal activity against Trypanosoma brucei brucei BS449 measured after 24 hrs using ATPlite-1 reagent by cell based luciferase reporter gene assay Trypanosoma brucei brucei 440.0 nM
Antitrypanosomal activity against Trypanosoma brucei brucei Trypanosoma brucei brucei BS449 measured after 48 hrs using ATPlite-1 reagent by cell based luciferase reporter gene assay Trypanosoma brucei brucei 321.0 nM
Antitrypanosomal activity against Trypanosoma brucei brucei BS449 measured after 72 hrs using ATPlite-1 reagent by cell based luciferase reporter gene assay Trypanosoma brucei brucei 349.0 nM
Antiparasitic activity against bloodstream form of Trypanosoma brucei brucei 449 after 24 hrs by ATPlite assay Trypanosoma brucei brucei 670.0 nM
Antiparasitic activity against bloodstream form of Trypanosoma brucei brucei 449 after 48 hrs by ATPlite assay Trypanosoma brucei brucei 530.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 -6.49 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.27 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.27 %

Related Entries

Cross References

Resources Reference
ChEBI 3614
ChEMBL CHEMBL790
DrugBank DB00878
DrugCentral 597
FDA SRS R4KO0DY52L
Human Metabolome Database HMDB0015016
KEGG C06902
PharmGKB PA164776863
PubChem 2713
SureChEMBL SCHEMBL3984
ZINC ZINC000014768621
CONTENTS